lt 727 - exfo-bio - rev. 03 - ikingdomofyork.com/skinsnob/exfobio_sm3.pdfmusa sapientum (banana)...
TRANSCRIPT
Exfo-Bio Pág. 1/25 FQ MKT_003 (03/13) SA 9664/14 LT 727 – Rev. 03
Exfo-Bio
DESCRIPTION
Glycerinated extract organic pulps of Yellow mombin (Spondias mombin), Mango
(Mangifera indica) and Banana (Musa sapientum).
COMPOSITION
INCI NAME CAS N° EINECS (I)/ELINCS (L)
Water (EU: Aqua, JPN: Onsen-Sui) 7732-18-5 231-791-2 (I)
Glycerin 56-81-5 200-289-5 (I)
Spondias Mombim Pulp Extract 1224966-11-3 -
Mangifera Indica (Mango) Pulp Extract
90063-86-8 290-045-4
Musa Sapientum (Banana) Pulp Extract
1224966-12-4 -
INTRODUCTION
Mammalian epidermis is a stratified epithelium that retains the ability to self renew
under both homeostatic and injury conditions by maintaining a population of mitotically
active cells in the hair follicles and innermost basal layer. The major barrier resides within
the exterior layers of the epidermis, which are sloughed off and repopulated from these
inner cells. The process of terminal differentiation begins when basal cells concomitantly
withdraw from the cell cycle and lose their ability to adhere to the basement membrane.
In the intermediate spinous layers, the cells reinforce a durable cytoskeletal framework of
keratin filaments to provide the mechanical strength necessary to resist physical trauma.
In the granular layers, lipids are produced inside lamellar bodies, keratins are
bundled into macrofibrils through their association with filaggrin, and a cornified envelope
(CE) is assembled by sequential incorporation of precursor proteins directly underneath
the plasma membrane. As the cell membrane disintegrates, the CE is assembled by cross-
linking several defined structural proteins by both disulfide and γ-glutamyl-ε-lysine
isopeptide bonds formed by the action of transglutaminases (TGases). The cross-linked
products, often of high molecular mass, are highly resistant to mechanical challenge and
proteolytic degradation, and their accumulation is found in a number of tissues and
processes, including skin, hair, blood clotting, and wound healing.
Recent experimental results have demonstrated an essential role for tight junctions
(TJs), located in the granular layer, in forming the epidermal barrier. This process of
Exfo-Bio Pág. 2/25 FQ MKT_003 (03/13) SA 9664/14 LT 727 – Rev. 03
differentiation from a mitotically active basal cell to a squame, a terminally differentiated
squamous cell, is maintained throughout life as part of epidermal regeneration. In general,
the complex mediates cell-to-cell adhesion and communication. In particular, TJs control
paracellular permeability and maintain cell polarity, which are often referred to as barrier
and fence function, respectively. Like other junction organelles, TJs are composed of
transmembrane and intracellular molecules. At the TJs, integral membrane proteins are
represented by occludin, junction adhesion molecule, and claudins. Claudins are members
of a family that comprises more than twenty proteins with four membrane-spanning
regions, two extracellular loops, and two cytoplasmic termini. Studies have demonstrated
that genetic ablation of claudin-1 induces neonatal death, which is associated with rapid
appearance of wrinkles in the skin and significant body dehydration.
The process of skin self-renewing is particularly associated with claudin-1, which
promotes epidermal differentiation, and with transglutaminases, which act as a cohesion
enhancer mainly in the stratum corneum (Figure 1). The entire process of human skin
replacement takes place in about 3-4 weeks in a young skin. However, over time and with
the ageing process, cell turnover rates decreases drastically, causing unbalanced tissue
repair and cell regeneration.
In this way, the modulation between transglutaminases activity and claudin-1
production plays a crucial role in the skin renew and homeostasis, because both increase
could lead a skin hardening and rough.
Exfo-Bio Pág. 3/25 FQ MKT_003 (03/13) SA 9664/14 LT 727 – Rev. 03
Figure 1. Transglutaminases and Claudin-1 activities in skin self-renewing.
Alpha hydroxyl acids (AHAs) are a class of chemical compounds that consist of a
carboxylic acid substituted with a hydroxyl group on the adjacent carbon. They may be
either naturally occurring or synthetic, and have been used for many years in the
cosmetics industry. They are often found in products claiming to reduce wrinkles or the
signs of aging, and improve the overall look and feel of the skin1. They are also used as
chemical peels available in a dermatologist's office, beauty and health spas and home kits,
which usually contain a lower concentration. Although their effectiveness is documented2
numerous cosmetic products have appeared on the market with unfounded claims of
performance3. Many well-known α-hydroxy acids are useful building blocks in organic
synthesis: the most common and simple are glycolic acid, lactic acid, citric acid, mandelic
acid. AHAs are generally safe when used on the skin as a cosmetic agent using the
recommended dosage. The most common side-effects are mild skin irritations, redness
and flaking. The severity usually depends on the pH and the concentration of the acid
used. Chemical peels tend to have more severe side-effects including blistering, burning
and skin discoloration, although they are usually mild and go away a day or two after
treatment. The FDA has also warned consumers that care should be taken when using
AHAs after an industry-sponsored study found that they can increase photosensitivity to
the sun.4
Calcium dependent enzymes that
catalyses covalent linking between
proteins and peptides in stratum
corneum
Transglutaminase (TGases)
Claudin-1
Tight junction (TJ) proteins: essential
for keratinocytes adherence.
Indicative of cell renewal.
Exfo-Bio Pág. 4/25 FQ MKT_003 (03/13) SA 9664/14 LT 727 – Rev. 03
Classical AHA can cause escess of dryness), redness, fissuring, scaling, and itching
resulting in an inflammatory cascade triggered by cytokines released from the epidermis in
response to barrier disruption. This effects cause descontinuidade of treatment.
Morphological variations in aging: Mechanical Skin Properties
The skin becomes thicker until maturity and then becomes thinner in women over
50-60 years old. Measurements of skin physical properties show that it becomes thinner,
stiffer, less tense and elastic with ageing (Diridollou et al., 2001).
Young's modules (elasticity modules) of the skin, a ratio between stress and
deformation, increases linearly with age. This is in agreement with data indicating that
skin becomes more rigid and less able to stretch in response to stress with age. This has
to be correlated with the increased crosslinking of collagen, the disorganization of the fibril
network and the large amount of free water in the dermis. Ageing decreases skin function
and causes clinical changes such as wrinkling, color changes (yellowish, patches,
pigmentation), and a loss of elasticity and adipose tissue (Diridollou et al., 2001). Sagging
is one of the major age-related morphological changes in the face. While wrinkles and
general changes in the face have been well studied, a recent method using photostandards
and 3 D analysis of replicas shows that women's cheeks begin to sagging when they reach
40 (Tsukahara et al., 2000). Recently measurements of site-related and age-dependent
variations in facial skin show that there is an overall increase of skin echogenicity and
thickness with age. The skin on the upper and lower lips, on the chin and infraorbital
regions is thicker than that on the central forehead, lateral forehead and cheeks. The facial
skin thickness becomes greater over the lateral regions of the forehead, lips and nose in
elderly subjects, and becomes thinner over the infraorbital regions (Pellacani e Seidenari,
1999). Fine lines are due to the gradual breakdown of collagen and elastin fibers, and they
are exacerbated by sun damage. Very deep wrinkles are associated with the muscle below
the skin surface. Muscles contract more with age to compensate for the loss of volume.
Excessive exposure to sunlight and smoking can cause major changes in the skin
(Lahmann et al., 2001). The skin may darken; develop very fine wrinkles, spots, and sag,
all of which are symptoms of photoageing. This is a very serious concern for middle-aged
women, especially women in Asia. Studies using the two point gap discrimination method
plus microneurographic recording in response to mechanical stimuli have also revealed
changes in tactile spatial discrimination in the elderly (Léveque et al., 2000).
The subcutaneous tissue is also concerned in ageing and it has a crucial role in the
skin ageing appearance. Menopause, the physiological cessation of menstruation caused
by decreased function of the ovaries, leads to thinning of the dermis, mainly due to a
Exfo-Bio Pág. 5/25 FQ MKT_003 (03/13) SA 9664/14 LT 727 – Rev. 03
decrease in the collagen content, atrophy of subcutaneous tissues and increased skin
dryness (Broniarczyk-Dyla e Joss-Wichman, 1999; Bonté, 2001).
Part of this reduced metabolism and function in the adipose tissue is due to a
decrease of SREBP-1 (Sterol regulatory element-binding protein 1), now well established
as a key transcription factor for the regulation of lipogenic enzyme genes in adipose and
other tissues, such as liver.
During the aging, the SREBP-1 gene is dormant, and as consequence, the reduction
of triglycerides accumulation into the adipocyte is also reduced.
COMPONENTS DESCRIPTION
Exfo-Bio is a Ecocert™ validated product composed by tropical fruits rich in
carbohydrates and some types alpha hydroxy acids (AHAs). The tropical fruits present in
the Exfo-Bio are banana, cajá and mango.
Banana (Musa Sapientum L.)
The medicinal properties of the banana are
part of the traditions of folk medicine. There are a
number of reports which associate the chemical
composition of banana with its therapeutical
properties. Extensive investigations regarding anti-
ulcerogenic and ulcer healing activities of plantain
banana have been carried out for the past 30 years.
Recently, M. sapientum was reported to have
antioxidant properties and a role in connective tissue
formation and maturation. Banana has a significant
amount of fructose and other sugars, carbohydrates,
flavonoids and some types of AHAs, such as malic
acid.
Exfo-Bio Pág. 6/25 FQ MKT_003 (03/13) SA 9664/14 LT 727 – Rev. 03
Cajá (Spondias mombin L.)
Spondias mombin is a tree, a species of flowering plant in the family
Anacardiaceae. It is native to the tropical Americas, including the West Indies. The tree
has been naturalized in parts of Africa, India and Indonesia. It is rarely cultivated. The
great fruit has a leathery skin and a thin layer of pulp. In Suriname's traditional medicine,
the infusion of the leaves is used as a treatment of
eye inflammation, diarrhea and venereal diseases.
It has several common names. Throughout the
Brazil it is called cajá, Spanish-speaking Caribbean
and Mexico it is called jobo. Among the English-
speaking Caribbean islands it is known as yellow
mombin or hog plum, while in Jamaica it is called
Spanish plum or gully plum. Cajá is a plant rich in
vitamins A, B1, B2, C, calcium, iron and
phosphorus. Cajá is referred as anti-inflammatory
and in traditional medicine, is used as a
adstringent, emetic, and against stomachache.
Mango (Mangifera indica L.)
The mango (Mangifera indica L.) is a rich source of nutritive compounds, including
ascorbic acid, carotenoids, and
polyphenols. Among tropical fruits ripe
mango had the highest gallic acid content
and total polyphenolics compared with
other fruits. The presence of
polyphenolics, carotenoids, and
antimutagens in the mango suggests
significant antioxidant and anticancer
activity, which have been demonstrated
by recent studies.
Exfo-Bio Pág. 7/25 FQ MKT_003 (03/13) SA 9664/14 LT 727 – Rev. 03
WHY Exfo-Bio?
Exfo-Bio is a cosmetic active Ecocert™ validated;
Exfo-Bio offers a mild cell renewing;
Exfo-Bio contains AHAs naturally present in tropical fruits;
Exfo-Bio improves epidermic cell turnover offering balance among main
cellular adhesion structures;
Exfo-Bio reinforces barrier offering cohesion among young corneocytes;
Exfo-Bio regulates the activity of genes related to adipogenesis, stimulating filling
in wrinkles and tissues;
Exfo-Bio promotes triple benefits to skin, working in: epidermis, dermis and
hypodermis.
Marketing Claims
Exfo-Bio presents the following main marketing claims:
� Mild cell renewing
� AHAs naturally present in tropical fruits
� Distinct mechanism of action from traditional AHAs
� Increases cell turnover without discomfort
� Keratolytic effect, but with enhanced barrier for greater cohesion between young
corneocytes
� Intelligent lipogenic effect, stimulating genes silenced with aging
� Improves general characteristics of the cutaneous relief
SAFETY ASSESSMENT
In vitro
Cytotoxic Potential (XTT Test) Citotoxicidade moderada
Phototoxicity (3T3-NRU) Non phototoxic
Irritative Potential (HET-CAM Test) Weakly irritant
Clinical
Primary dermal irritation (Open Test, PC5) Good cutaneous compatibility
Alergenic Potential (HRIPT) Non alergenic
Exfo-Bio Pág. 8/25 FQ MKT_003 (03/13) SA 9664/14 LT 727 – Rev. 03
EFFICACY ASSESSMENT In vitro and ex vivo
Evaluation of keratolytic effect (epidermal activity)
a) Stimulation of Claudin-1 gene expression
Figure 2. CLAUDIN-1 mRNA gene expression by human keratinocytes treated with different concentrations of
Exfo-Bio during 6 hours. The data are presented as the mean of relative amounts of CLAUDIN-1 in relation to
the control group, of three individual experiments.
CLAUDIN-1 mRNA expression was evaluated in human keratinocytes cultures and
detected by real-time PCR (Figure 2). Exfo-Bio at 0.04 % (v/v) concentration induced
relevant increase in CLAUDIN-1 expression, reaching 1.65 fold in relation to non-treated
control. This result indicates an increase in cellular adherence and renewal by Exfo-Bio.
0,0
0,5
1,0
1,5
2,0
2,5
CLA
UD
IN-1
(m
RN
A)
ge
ne
ex
pre
ssio
n
ex
pre
ssio
n
rela
ted
to
co
ntr
ol
con
tro
l
Exfo-Bio 0.04 % (v/v)
Controle
1.65 x
Exfo-Bio Pág. 9/25 FQ MKT_003 (03/13) SA 9664/14 LT 727 – Rev. 03
b) Immunohistochemical reactivity of Claudin-1
Figure 3. The effects of Exfo-Bio (0.04 % v/v) on CLAUDIN-1 immunoreactivity in human skin explants after 6
hours incubation. Histological sections were immunostained by rabbit antiserum directed against CLAUDIN-1 in
untreated (a) and treated explants (b) (40 x magnifications).
For immunohistochemical analysis, skin sections obtained from plastic-surgery patients
were treated with Exfo-Bio in the concentration of 0.04 % (v/v) during 6 hours (figure 3).
Corroborating the results obtained in gene expression assays, the visualization of skin
slides showed an increased marked of CLAUDIN-1 in the cell membrane of keratinocytes
compared to the control group.
c) Histological Analysis of the Epidermis and Skin Barrier
Figure 4. Histological evaluation of human skin explants treated with Exfo-Bio (0.04 % v/v) during 6 hours
incubation. Tissue integrity was demonstrated between the untreated (a) and treated (b) sections stained by
hematoxilin-eosin (40 x magnifications).
a. Control b. Exfo-Bio 0.04 % (v/v)
a. Control b. Exfo-Bio 0.04 % (v/v)
Exfo-Bio Pág. 10/25 FQ MKT_003 (03/13) SA 9664/14 LT 727 – Rev. 03
Histological evaluation of human skin sections was performed with the purpose to
verify the skin appearance after treatment with Exfo-Bio, particularly in epidermis layers
(figure 4). The treatment at concentration of 0.04 % (v/v) during 6 hours has promoted
an increased in epidermis thickness and keratinocytes appearance.
d) Measurement of Transglutaminase production
Figure 5. Transglutaminase activity by human keratinocytes treated with different concentrations of Exfo-Bio
during 6 hours. Data are presented in percentage related to the control group, of three individual experiments
(ANOVA, Tukey).
In the Figure 5 are demonstrated the effects of Exfo-Bio in transglutaminase activity.
Decreases up to 4.4, 5.7 and 13.5 % in the enzymatic activity, at concentrations of 0.01,
0.02 and 0.04 % (v/v), respectively, were found compared to control group. Considering
that transglutaminases are crucial for cornified envelope formation, the reduction in its
activity could lead to a smooth keratolytic activity, approaching of a natural process of cell
renewal.
-20
-15
-10
-5
0
5
(% e
m r
ela
ção
ao
co
ntr
ole
)
con
tro
le) - 4.4 %
- 5.7 %
- 13.5 %
0.01 0.02 0.04
Exfo-Bio % (v/v)
*
Ati
vid
ad
e d
a T
ran
sglu
tam
ina
se
Tra
nsg
luta
min
ase
Exfo-Bio Pág. 11/25 FQ MKT_003 (03/13) SA 9664/14 LT 727 – Rev. 03
Evaluation of matrix extracellular synthesis (dermal activity)
a) Stimulation of Pro-Collagen gene expression
Figure 6. Pro-Collagen mRNA gene expression by human fibroblasts treated with different concentrations of
Exfo-Bio during 24 hours. The data are presented as the mean of relative amounts of Pro-Collagen in relation to
the control group, of three individual experiments.
The levels of Pro-Collagen expression were determined by real-time PCR (Figure 6)
in different concentrations of Exfo-Bio (0.01, 0.02 and 0.04 % (v/v)). The Pro-Collagen
gene was induced in all concentrations, reaching levels of 7.5 fold higher than non-treated
control group. This stimulatory ability of Exfo-Bio in this extracellular matrix component is
essential for dermal arrangement, contributing to reduced process of wrinkles formation.
0
2
4
6
8
10
Pro
-co
lla
ge
n (
mR
NA
) g
en
e e
xp
ress
ion
ex
pre
ssio
n
rela
ted
to
co
ntr
ole
con
tro
le
Exfo-Bio % (v/v)
0.01 0.02 0.04
+ 4.4x
+ 5.2x
+ 7.5x
Exfo-Bio Pág. 12/25 FQ MKT_003 (03/13) SA 9664/14 LT 727 – Rev. 03
Evaluation of lipogenic potential (hypodermal activity)
a) Stimulation of SREBP-1 gene expression
Figure 7. SREBP-1 mRNA gene expression by human adipocytes treated with different concentrations of Exfo-
Bio during 6 hours. The data are presented as the mean of relative amounts of SREBP-1 in relation to the control
group, of three individual experiments.
SREBP-1 (sterol regulatory element-binding protein) mRNA expression in human
adipocytes cultures was detected by real-time PCR. As seen in Figure 7, cell treatment
with Exfo-Bio at 0.01, 0.02 and 0.04 % (v/v) induced relevant increase in SREBP-1
expression. The 0.04 % (v/v) concentration promoted an increase of 1.7 fold in relation to
non-treated control. This result is an indicative of adipogenesis stimulation by Exfo-Bio.
0,0
0,5
1,0
1,5
2,0
2,5
SR
EB
P-1
(m
RN
A)
ge
ne
ex
pre
ssio
n
ex
pre
ssio
n
rela
ted
to
co
ntr
ol
Exfo-Bio (% v/v)
0.01 0.02 0.04
+1.6x
+1.6x
+1.7x
Exfo-Bio Pág. 13/25 FQ MKT_003 (03/13) SA 9664/14 LT 727 – Rev. 03
b) Measurement of NEFA release
Figure 8. NEFA (non-esterified fatty acids) release by human adipocytes treated with different concentrations of
Exfo-Bio during 6 hours. Data are presented in percentage related to the control group, of three individual
experiments (ANOVA, Tukey).
Figure 8 represents NEFA (non-esterified fatty acids) measurements in human
adipocyte culture. Our findings demonstrated that Exfo-Bio at concentrations of 0.01,
0.02 and 0.04 % (v/v), promoted significant decreases in NEFA release by cell cultures,
reaching levels 30.2 % lower, in relation to non-treated cultures. This result is a clearly
consequence of increase in SREBP-1 expression, which is an inducer of lipid accumulation.
Clinical Efficacy
1. Dermatological Assessment
The clinical efficacy Exfo-Bio was verified through evaluations performed by
Dermatologist, according to the attributes: skin hydration; wrinkles; brightness; spots;
firmness; softness, at different experimental times: on (D1) before using the product, and
after 28 days use (D28). 35 female volunteers aged from 35 to 55 years old were selected
to this study.
The first day evaluation performed on (D1) before using the product, established the
initial state of the skin of the volunteer. After 28 days of use (D28), it was established the
intensity of the possible improvement related to the product effect.
The results of assessments are shown in Figures 9 to 16, using the percentage of
volunteers that corresponds to each answer.
-40
-30
-20
-10
0
10
NE
FA
A
(% r
ela
ted
to
co
ntr
ol)
con
tro
l)
Exfo-Bio % (v/v)
0.01 0.02 0.04
- 8.5 %
- 18 %
- 30.2 %
Exfo-Bio Pág. 14/25 FQ MKT_003 (03/13) SA 9664/14 LT 727 – Rev. 03
Results:
1. Skin Hydration
In relation to hydration, the skin of volunteer:
10%
60%
27%
3%
17%
63%
20%
0%0%
20%
40%
60%
80%
very hydrated Is hydrated little hydrated is not hydrated
Perc
ent
age o
f volu
nte
ers
(%)
D1
D28
Figure 9: Dermatological Assessment for “Hydration”
2. Fine Wrinkles
Regarding fine wrinkles:
40%
53%
7%
0%
43%
53%
3%0%
0%
20%
40%
60%
Slight Moderate Intense absence
Pe
rce
nta
ge
of
vo
lun
tee
rs (
%)
D1
D28
Figure 10: Dermatological Assessment for “Fine wrinkles”.
Exfo-Bio Pág. 15/25 FQ MKT_003 (03/13) SA 9664/14 LT 727 – Rev. 03
3. Eye Wrinkles
Regarding eye wrinkles:
37%
47%
17%
0%
43%40%
17%
0%
0%
20%
40%
60%
Slight Moderate Intense absence
Per
cen
tag
e o
f vo
lun
teer
s (%
)
D1
D28
Figure 11: Dermatological Assessment for “Eye wrinkles”
4. Skin brightness
Regarding the brightness of the skin:
43% 43%
7% 7%
27%
57%
17%
0%
0%
20%
40%
60%
80%
Slight Moderate Intese absence
Per
cen
tag
e o
f vo
lun
teer
s (%
)
D1
D28
Figure 12: Dermatological Assessment for “Brightness”
Exfo-Bio Pág. 16/25 FQ MKT_003 (03/13) SA 9664/14 LT 727 – Rev. 03
5. Spots
Regarding the spots, the skin of voluntary:
10%
37%
53%
0%7%
40%
53%
0%0%
20%
40%
60%
80%
With many
spots
Spots Little spots Absence
Perc
enta
ge o
f vol
unt
eers
(%
)
D1
D28
Figure 13: Dermatological Assessment for “Spots”
6. Firmness
Regarding the firmness, the skin of voluntary:
10%
40%
50%
0%
10%
47%43%
0%0%
20%
40%
60%
80%
Very firm Firm Little firm Is not firm
Pe
rcen
tag
e o
f vo
lun
teer
s (%
)
D1
D28
Figure 14: Dermatological Assessment for “Firmness”
Exfo-Bio Pág. 17/25 FQ MKT_003 (03/13) SA 9664/14 LT 727 – Rev. 03
7. Softness
Regarding the softness, the skin of voluntary:
3%
57%
33%
3%7%
67%
23%
3%
0%
20%
40%
60%
80%
Very softness Softness Little softness Is not
softness
Pe
rcen
tage
of v
olu
nte
ers
(%)
D1
D28
Figure 15: Dermatological Assessment for “Softness”
8. Signs of aging
Figure 16: Dermatological Assessment l for “Signs of aging”
Regarding the signs of aging:
30%
63%
7%
0%
30%
63%
7%
0%
0%
20%
40%
60%
80%
Slight Moderate Intense Absence
Percentage of volunteers (%)
D1
D28
Exfo-Bio Pág. 18/25 FQ MKT_003 (03/13) SA 9664/14 LT 727 – Rev. 03
2. Cosmetic Appreciability Assessment
This study intends to check the cutaneous acceptability and the cosmetic
appreciability of SERUM FACIAL ANTIAGING Exfo-Bio after 28 days (D28), under
normal conditions of use.
35 female volunteers aged from 35 to 55 years old were selected to this study.
The cutaneous acceptability was:
� Checked every day, by the volunteers themselves at home;
� Controlled after visual examination of the experimental area, by a
dermatologist or the co-investigator or the technician, under his authority, and after
questioning of the volunteers.
The cosmetic appreciability was verified, using a target questionnaire answered by
the volunteers after product’s application (Figures 17 to 26).
Results:
1. Wrinkles and Fine Lines Reduction:
Wrinkles and fine lines reduction after 28 days
42%
18%24%
15%
0%0%
20%
40%
60%
80%
Excellent
Efficacy
Very good
efficacy
Good Efficacy Regular
Efficacy
Not have good
efficacy
Per
cen
tag
e o
f vo
lun
teer
s (%
)
Figure 17: Perception of volunteers for the "wrinkles and fine lines”
42% of the volunteers observed excellent efficacy concerning “wrinkles and fine lines”
Exfo-Bio Pág. 19/25 FQ MKT_003 (03/13) SA 9664/14 LT 727 – Rev. 03
2. Eye Wrinkles and Fine Lines Reduction after 28 days
Eye wrinkles and fine lines reduction after 28 days
33%
18%24%
21%
3%
0%
20%
40%
60%
80%
Excellent
efficacy
Very good
efficacy
Good efficacy Regular
efficacy
Not have good
efficacy
Per
cen
tag
e o
f vo
lun
teer
s (%
)
Figure 18: Perception of volunteers for the "eye wrinkles and fine lines”
33% of the volunteers observed excellent efficacy concerning “eye wrinkles and fine lines”
3. Filling wrinkles
Filling wrinkles after 28 days
9%
39%
15%18% 18%
0%
20%
40%
60%
80%
Very
perceptible
Perceptible Little
perceptible
Very little
perceptible
Is not
perceptible
Per
cen
tag
e o
f vo
lun
teer
s (%
)
Figure 19: Perception of volunteers for the "filling wrinkles”
39% of the volunteers observed perceptible concerning “filling wrinkles”
Exfo-Bio Pág. 20/25 FQ MKT_003 (03/13) SA 9664/14 LT 727 – Rev. 03
4. Improving Skin Tone and Firmness
Improving skin tone and firmness after 28 days
36%
15%
30%
18%
0%0%
20%
40%
60%
80%
Excellent
efficacy
Very good
efficacy
Good efficacy Regular
efficacy
Not have good
efficacy
Per
cen
tag
e o
f vo
lun
teer
s (%
)
Figure 20: Perception of volunteers for the "Skin tone and firmness”
36% of the volunteer observed excellent efficacy concerning “Skin tone and firmness
5. Spots Clearing
Spots clearing after 28 days
24%
9%
36%
3%
15%
0%
20%
40%
60%
80%
Excellent
efficacy
Very good
efficacy
Good efficacy Regular
efficacy
Not have
good efficacy
Po
rcen
tag
em d
e vo
lun
tári
os
(%)
Figure 21: Perception of volunteers for the "spots clearing”
36% of the volunteers observed good efficacy concerning “spots clearing”
Per
cen
tag
e o
f vo
lun
teer
s (%
)
Exfo-Bio Pág. 21/25 FQ MKT_003 (03/13) SA 9664/14 LT 727 – Rev. 03
6. Skin Softer
Skin softer after 28 days
55%
27%
12%6%
0%0%
20%
40%
60%
80%
Very softer Softer Little softer Very little
softer
Not have
difference
Po
rcen
tag
em d
e vo
lun
tári
os
(%)
Figure 22: Perception of volunteers for the "softer”
55% of the volunteers observed very softer concerning “softer”
7. Skin Brighter
Skin brighter after 28 days
33% 33%
18%12%
3%
0%
20%
40%
60%
80%
Very brighter Brighter Little brighter Very little
brighter
Not have
difference
Per
cen
tag
e o
f vo
lun
teer
s (%
)
Figure 23: Perception of volunteers for the "brighter”
33% of the volunteers observed very brighter and brighter concerning “brighter”
Per
cen
tag
e o
f vo
lun
teer
s (%
)
Exfo-Bio Pág. 22/25 FQ MKT_003 (03/13) SA 9664/14 LT 727 – Rev. 03
8. Skin Hydration
Skin hydratation after 28 days
45%
30%
12%6% 6%
0%
20%
40%
60%
80%
Very more
hydrated
More
hydrated
Little hydrated Very little
hydrated
Not have
difference
Per
cen
tag
e o
f vo
lun
teer
s(%
)
Figure 24: Perception of volunteers for the "hydration”
45% of the volunteers observed very more hydrated concerning “hydratation”
9. Product Performance
Product performance after 28 days
36%
27%30%
6%0%
0%
20%
40%
60%
80%
Extremely
satisfied
Very satisfied Satisfied Indifference UnsatisfiedPo
rcen
tag
em d
os
volu
ntá
rio
s (%
)
Figure 25: Perception of volunteers for the "Product performance”
36% of the volunteers said that they were extremely satisfied and satisfied concerning “Product performance”
Skin Hydration after 28 days
Per
cen
tag
e o
f vo
lun
teer
s (%
) P
erce
nta
ge
of
volu
nte
ers
(%)
Exfo-Bio Pág. 23/25 FQ MKT_003 (03/13) SA 9664/14 LT 727 – Rev. 03
10. Buying Intention
Buying intention
67%
24%
3%6%
0%0%
20%
40%
60%
80%
Certainly
yes
Maybe yes Indifference Maybe not Certainly not
Po
rcen
tag
em d
e vo
lun
tári
os
Figure 26: Perception of volunteers for the "Buying intention”
67% of the volunteers answered certainly yes concerning “buying intention”
APLICATION AND USAGE INDICATIONS
Exfo-Bio can be used in face and body formulations to all skin types.
SUGGESTED CONCENTRATION
From 1.0 to 5.0% (w/w).
BIBLIOGRAPHICAL REFERENCES
1. Bazzoni G, Dejana E. Keratinocyte junctions and the epidermal barrier: how to make a skin-
tight dress. J Cell Biol 156(6):947-949, 2002.
2. Segre JA. Epidermal barrier formation and recovery in skin disorders. J Clin Invest 116:1150-
1158, 2006.
3. Kempers S, Katz HI, Wildnauer R, Green B. An evaluation of the effect of an alpha hydroxy
acid-blend skin cream in the cosmetic improvement of symptoms of moderate to severe
xerosis, epidermolytic hyperkeratosis, and ichthyosis. Cutis 61 (6):347–350, 1998.
4. Alpha hydroxy acids for skin care. Cosm Dermatol Sup 1–6, 1994.
5. Garg K, Kachhawa D. Chemical peeling - glycolic acid versus trichloroacetic acid in melasma.
Indian J Dermatol Venereol Leprol 67(2):82-84, 2001.
6. Kurtzweil P. Alpha hydroxy acids for skin care. FDA Consumer.
http://www.cfsan.fda.gov/~dms/fdacaha.html, 1998.
Per
cen
tge
of
volu
nte
ers
(%)
Exfo-Bio Pág. 24/25 FQ MKT_003 (03/13) SA 9664/14 LT 727 – Rev. 03
7. Agarwal PK, Singh A, Gaurav K, Goel S, Khanna HD, Goel RK. Evaluation of wound healing
activity of extracts of plantain banan (Musa sapientum var. paradisiaca) in rats. Indian J Exp
Biol 47:32-40, 2009.
8. Anhwange BA, Ugye TJ, Nyiaatagher TD. Chemical composition of Musa sapientum (banana)
peels. Elec J Envir Agricul Food Chem 8(6):437-442, 2009.
9. Ayoka AO, Akomolafe RO, Akinsomisoye OS, Ukponmwan OE. Medicinal and economic value
of Spondias mombin. African J Biom Res 11:129-136, 2008.
10. Feitosa SS. Nutrição mineral e adubação da cajazeira (Spondias mombin L.) na zona da mata
Paraibana. Areia – PB: 50 p. Dissertação (Solos e Nutrição de Plantas), 2007.
11. Filgueiras HAC, Moura CFH, Alves RE. Caracterização de frutas nativas da América Latina.
Jaboticabal: Funep, 2000, 66 p.: il. ; 21 cm (Série Frutas Nativas, 9).
12. Sacramento CK, Souza FX. Cajá (Spondias mombin L.). Jaboticabal: Funep, 2000. 42p.
(Série Frutas Nativas, 4).
13. Percival SS, Talcott ST, Chin ST, Mallak AC, Lounds-Singleton A, Pettit-Moore J. Neoplastic
transformation of BALB/3T3 cells and cell cycle of HL-60 cells are inhibited by mango
(Mangifera indica L.) juice and mango juice extracts. J Nutr 136:1300-1304, 2006.
14. Sellés AJN, Castro HTV, Agüero-Agüero J, González-González J, Naddeo F, Simona F,
Rastrelli L. Isolation and quantitative analysis of phenolic antioxidants, free sugars, and
polyols from mango (Mangifera indica L.) stem bark aqueous decoction used in Cuba as a
nutritional supplement. J Agric Food Chem 50(4): 762-766, 2002.
15. Diridollou S, Vabre V, Berson M, Vaillant L, Black D, Lagarde M, Gregoire JM, Gall Y, Patat F.
Skin ageing: changes of physical properties of human skin in vivo. Internat J Cosm Sci,
2001; 23: 353-62.
16. Tsukahara K, Takema Y, Fujimura T, Moriwaki S, Kitahara T, Imokawa G. Determination of
age-related changes in the morphological structures (sagging) of the human cheek using a
photonumeric scale and three-dimensional surface parameters. Internat J Cosm Sci, 2000;
22: 247-58.
17. Pellacani G, Seidenari S. Variations in facial skin thickness and echogenicity with site and
age. Acta Derm Venereol, 1999; 79: 366-9.
18. Lahmann C, Bergemann J, Harrison G, Young AR. Matrix metalloproteinase-1 and skin ageing
in smokers. The Lancet, 2001; 357: 935-6.
19. Léveque JL, Dresler J, Ribot-Ciscar E, Roll JP, Poelman C. Changes in tactile spatial
discrimination and cutaneous coding properties by skin hydration in the elderly. J Invest
Dermatol, 2000; 115: 454-8.
20. Broniarczyk-Dyla G, Joss-Wichman E. Aging of the skin during menopause. Med Sci Monit,
1999; 5: 1024-9.
21. Bonté F. Régulations hormonales cutanées et utilisation d'extraits végétaux correcteurs par
voie topique. Phytothérapie, 2001; 25-8.
Exfo-Bio Pág. 25/25 FQ MKT_003 (03/13) SA 9664/14 LT 727 – Rev. 03
Document Written by Reviewed by: Approved by: Controlled by:
R&D Dept. MKT Dept. P&D Director QA Dept.
The information contained in this Literature is provided in good faith. We recommend the test of our products in order to verify the convenience of their use before adopting them at industrial level. Such information shall not be understood as concession or permission to use the methods or compositions covered by any patent. This material reproduction is prohibited without the
CHEMYUNION QUÍMICA LTDA authorization.